Banca de DEFESA: NATÁLIA LÔRES LOPES

Uma banca de DEFESA de DOUTORADO foi cadastrada pelo programa.
STUDENT : NATÁLIA LÔRES LOPES
DATE: 05/02/2021
TIME: 09:00
LOCAL: Laboratório de Quimioterapia Experimental em Parasitologia Veterinária (On line)
TITLE:

Evaluation of clinical safety and comparative study of the efficacy of oclacitinib in the treatment of cats with flea allergy dermatitis

KEY WORDS:

Key words: cats, pruritus,flea, oclacitinb

PAGES: 90
BIG AREA: Ciências Agrárias
AREA: Medicina Veterinária
SUBÁREA: Clínica e Cirurgia Animal
SPECIALTY: Clínica Veterinária
SUMMARY:

Pruritus is one of the most common clinical signs in veterinary dermatology. Among the different etiologies, it is frequently seen in cats with allergic dermatitis to flea bites. Corticosteroids and cyclosporine are the drugs most used today as antipruritic therapy, but they can lead to the occurrence of several adverse effects. Oclacitinib, a janus kinase inhibitor, has been used to control itchiness in dogs effectively and safely, with few adverse effects. Few studies are available in cats, with differences between doses and administration regimen, and there is no safety study available for the species. The objectives of the study were: (i) to verify the safety of Oclacitinib when used in cats; (ii) determine the effectiveness in treating cats with allergic dermatitis to flea bites. To determine the safety of using oclacitinib in cats, 30 cats were used, divided into three groups (oclacitinib 1 mg / kg orally every 12 hours, oclacitinib 2 mg / kg orally every 12 hours and a group of placebo receiving starch pills every 12 hours). The treatment lasted 28 days. The animals were submitted to clinical evaluation and blood collection for complete blood count, serum biochemistry (gammaglutamyl transferase (GGT), alamine aminotransferase (ALT), aspartate transferase (AST), alkaline phosphatase (FA), urea, creatinine, bilirubin, glucose, fructosamine, cholesterol, triglycerides, total proteins and albumin) on days -2, +3, +7, +14, +21 and +28 and abdominal ultrasound with cystocentesis urine collection for EAS on days -2, +14 and + 28.

Oclacitinib was well tolerated, only adverse effects were observed and they were vomiting in two animals and soft stools in two cats of the ten animals in the 2 mg / kg group. No significant hematological changes were observed. Liver and kidney enzymes remained normal throughout the study and only a significant increase in fructosamine levels was observed in the two treated groups, but remained within the reference values. There was no significant difference in the mean values obtained for urinary density, pH, or in the urinary creatinine protein ratio. To determine the efficacy of oclacitinib in the treatment of cats with flea allergic dermatitis, 14 cats diagnosed with flea allergic dermatitis were included and were allocated into 2 groups (group 1- oclacitinib 1 mg / kg orally every 12 hours for 7 days; group 2- prednisolone 2 mg / kg orally every 12 hours for 7 days). The animals were evaluated for the evolution of the lesions and the presence and intensity of pruritus using the VAS, FEDESI and SCORFAD scales on days 0, +1, +3 and +7. It was concluded that oclacitinib was well tolerated in cats at doses of 1 mg / kg and 2 mg / kg and appeared to be safe when administered every 12 hours for 28 days. Further studies are needed to assess whether oclacitnib is a viable option for the control of itching in cats.

BANKING MEMBERS:
Presidente - 4563410 - JULIO ISRAEL FERNANDES
Interno - 2318733 - DANIEL DE ALMEIDA BALTHAZAR
Externo à Instituição - ANDRE LUIZ RODRIGUES ROQUE - FIOCRUZ
Externo à Instituição - CAROLINA FRANCHI JOÃO - UFU
Externa à Instituição - REGINA HELENA RUCKERT RAMADINHA - UFRRJ